TABLE 3.
Difference in change of A1C after start of metformin therapy per genotype
| SNP | Adjusted difference in A1C change (%)* | P | P after Bonferroni correction† |
|---|---|---|---|
| rs894680 | −0.15 | 0.19 | 1.00 |
| rs2018675 | 0.029 | 0.80 | 1.00 |
| rs2440154 | 0.11 | 0.35 | 1.00 |
| rs2440155 | 0.23 | 0.10 | 0.90 |
| rs16960201 | — | — | — |
| rs2453568 | 0.09 | 0.42 | 1.00 |
| rs2244280 | 0.23 | 0.062 | 0.56 |
| rs2289669 | −0.30 | 0.005 | 0.045 |
| rs1961669 | 0.16 | 0.27 | 1.00 |
| rs2453594 | 0.26 | 0.036 | 0.32 |
| rs2453589 | 0.12 | 0.28 | 1.00 |
| rs2165894 | 0.28 | 0.019 | 0.17 |
*
Additive model (number of variant allele and dose effect), adjusted for age, sex, A1C level before start, prescribed dose of metformin, change in prescribed doses of sulfonylurea, time from diagnosis of diabetes to start of metformin therapy, and estimated glomerular filtration rate.
†
We corrected for nine independent tests because one tagging SNP had no genetic variation and 2 × 2 tagging SNPs were in linkage disequilibrium.